Transplant Care Coverage
Continuing patient access to innovative treatment options
A new development may impact transplant patient care.
Send Your support
Transplant Care Coverage
Continuing patient access to innovative treatment options
Transplant Care
Coverage
Continuing patient access to innovative treatment options
Send Your support
What is going on?
The entities responsible for determining Medicare coverage are reviewing the clinical evidence for post-transplant tests, such as CareDx’s AlloMap and AlloSure. In addition,
on a yearly basis insurance companies are looking at coverage for these tests.
These reviews could potentially impact your access to these tests.
What is going on?
The entities responsible for determining Medicare coverage are reviewing the clinical evidence for post-transplant tests, such as CareDx’s AlloMap and AlloSure.
In addition, on a yearly basis insurance companies are looking at coverage for these tests.
These reviews could potentially impact your access to these tests.
Why does this matter to you?
AlloMap and AlloSure help detect issues with transplants earlier than traditional testing while also helping patients avoid invasive procedures like biopsies. These tests have been trusted by the transplant community for over 15 years for heart transplant recipients and over 5 years in kidney transplant recipients.
How can you help?
We encourage you to voice your opinion on the importance of these tests by submitting the form below. Your response will be sent to the agencies responsible for these reviews. Feel free to include your own personal AlloSure or AlloMap story for a more direct impact on your care.
Example Letter
I am an organ transplant patient, and I am writing concerning access and coverage for post-transplant tests, including Medicare and private insurance coverage.
AlloSure (donor-derived cell-free DNA) and AlloMap (gene-expression profiling) are important to transplant care. Using these tests to monitor the health of my transplant helps my care team detect issues, including rejection, earlier than other tests, while also allowing me to avoid invasive procedures such as biopsies.
I ask that you please ensure continued availability of these critical tests for monitoring transplant health by maintaining access to Medicare coverage and ensuring private insurance coverage.
Transplant is a gift, and monitoring organ rejection is a serious issue, and it is important that patients have access to these innovative and non-invasive testing solutions to help them and their doctor’s in their transplant journey.
Our Patient Care Managers (PCMs) can help get you scheduled for your next AlloSure
TALK TO PCM
